Randall McCarthy
Medical · Waycross, GANPI 1891875878
Payments from drug & device makers
Across 205 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$728
- Lilly USA, LLC$282
- Pfizer$274
- Amgen$177
- AbbVie$165
- Boston Scientific$158
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,367100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $728 |
| Lilly USA, LLC | 19 | $282 |
| Pfizer | 15 | $274 |
| Amgen | 12 | $177 |
| AbbVie | 10 | $165 |
| Boston Scientific | 8 | $158 |
| Otsuka America Pharmaceutical, Inc. | 7 | $146 |
| Bayer | 9 | $146 |
| Boehringer Ingelheim | 8 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $127 |
| AstraZeneca | 6 | $105 |
| Corium, LLC | 3 | $90 |
| Dexcom, Inc. | 5 | $84 |
| Abbott | 5 | $83 |
| E.r. Squibb & Sons, L.L.C. | 5 | $78 |
| Merck | 5 | $70 |
| Paratek Pharmaceuticals, Inc. | 3 | $59 |
| Astellas Pharma US Inc | 3 | $59 |
| Corcept Therapeutics | 3 | $58 |
| GSK | 3 | $53 |
| Johnson & Johnson | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Mylan Specialty L.p. | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$3,367 in reported general payments places this provider in the 75th percentile of 950 medical providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 123 | $102,787 |
| OzempicSemaglutide | 72 | $72,679 |
| JanuviaSitagliptin Phosphate | 77 | $70,319 |
| MounjaroTirzepatide | 56 | $58,069 |
| TrulicityDulaglutide | 28 | $31,434 |
| RybelsusSemaglutide | 23 | $25,630 |
| JardianceEmpagliflozin | 33 | $22,658 |
| XareltoRivaroxaban | 31 | $21,915 |
| FarxigaDapagliflozin Propanediol | 28 | $18,244 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $18,180 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $13,456 |
| EntrestoSacubitril/Valsartan | 13 | $12,178 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $12,107 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $10,477 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $10,320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $274 | $106,153134 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $728 | $103,053108 claims |
| MerckJanuvia, Janumet, Janumet Xr | $70 | $91,116105 claims |
| Lilly USA, LLCMounjaro, Trulicity | $282 | $89,50384 claims |
| AstraZenecaFarxiga, Symbicort | $105 | $26,72151 claims |
| Boehringer IngelheimJardiance | $136 | $22,65833 claims |
| Johnson & JohnsonXarelto | $46 | $21,91531 claims |
| GSKTrelegy Ellipta | $53 | $18,18028 claims |
| AbbVieLinzess, Synthroid | $165 | $13,63290 claims |
| NovartisEntresto | $20 | $12,17813 claims |
| Astellas Pharma US IncMyrbetriq | $59 | $9,51520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 950 medical providers in Georgia.
Other medical in Waycross
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
- Sally BrumbillLithia Springs$110K
- Danna Dennis-CalderAtlanta$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.